ReviewCerebellum & ataxias2017
Immune-mediated cerebellar ataxias: from bench to bedside.
Review in Cerebellum & ataxias, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Diagnostic Criteria for Primary Autoimmune Cerebellar Ataxia-Guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias.Cerebellum (London, England) · 2020Guideline
- Assessment of anti-GAD65-associated cerebellar ataxia withAnnals of nuclear medicine · 2023Trial
- Clinical Characteristics and Longitudinal Videonystagmographic Monitoring in an Adolescent with Vimentin Antibody-Positive Cerebellar Ataxia: A Case Report.Cerebellum (London, England) · 2026Article
- A Scoping Review of POLG-Related Cerebellar Ataxia: Insights and Clinical Perspectives.Tremor and other hyperkinetic movements (New York, N.Y.) · 2025Article
- Acute Cerebellar Manifestations without Limbic Involvement in GABACerebellum (London, England) · 2024Review
- Cell-Autonomous Processes That Impair Xenograft Survival into the Cerebellum.Cerebellum (London, England) · 2022Review
- A Breakdown of Immune Tolerance in the Cerebellum.Brain sciences · 2022Review
- Identification of the Prodromal Symptoms and Pre-Ataxic Stage in Cerebellar Disorders: The Next Challenge.International journal of environmental research and public health · 2021Article
- Opinion and Special Articles: Cerebellar Ataxia and Liver Failure Complicating IPEX Syndrome.Neurology · 2021Article
- Inpatient vs Outpatient Evaluation of Suspected Paraneoplastic Cerebellar Degeneration.Neurology. Clinical practice · 2021Article
- Immune-tolerance to human iPS-derived neural progenitors xenografted into the immature cerebellum is overridden by species-specific differences in differentiation timing.Scientific reports · 2021Article
- Immune-Mediated Cerebellar Ataxias: Clinical Diagnosis and Treatment Based on Immunological and Physiological Mechanisms.Journal of movement disorders · 2021Article
- Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome.Journal of clinical neurology (Seoul, Korea) · 2020Review
- Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias.International journal of molecular sciences · 2020Review
- Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- The neurological update: therapies for cerebellar ataxias in 2020.Journal of neurology · 2020Review
- Consensus Paper. Cerebellar Reserve: From Cerebellar Physiology to Cerebellar Disorders.Cerebellum (London, England) · 2020Review
- Neurochondrin Antibody Serum Positivity in Three Cases of Autoimmune Cerebellar Ataxia.Cerebellum (London, England) · 2019Article
- Reaction of antibodies toWorld journal of gastroenterology · 2019Article
- The Comprehensive Management of Cerebellar Ataxia in Adults.Current treatment options in neurology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
The cerebellum is a vulnerable target of autoimmunity in the CNS. The category of immune-mediated cerebellar ataxias (IMCAs) was recently established, and includes in particular paraneoplastic cerebellar degenerations (PCDs), gluten ataxia (GA) and anti-GAD65 antibody (Ab) associated-CA, all characterized by the presence of autoantibodies. The significance of onconeuronal autoantibodies remains uncertain in some cases. The pathogenic role of anti-GAD65Ab has been established both in vitro and in vivo, but a consensus has not been reached yet. Recent studies of anti-GAD65 Ab-associated CA have clarified that (1) autoantibodies are generally polyclonal and elicit pathogenic effects related to epitope specificity, and (2) the clinical course can be divided into two phases: a phase of functional disorder followed by cell death. These features provide the rationale for prompt diagnosis and therapeutic strategies. The concept "Time is brain" has been completely underestimated in the field of immune ataxias. We now put forward the concept "Time is cerebellum" to underline the importance of very early therapeutic strategies in order to prevent or stop the loss of neurons and synapses. The diagnosis of IMCAs should depend not only on Ab testing, but rather on a rapid and comprehensive assessment of the clinical/immune profile. Treatment should be applied during the period of preserved cerebellar reserve, and should encompass early removal of the conditions (such as remote primary tumors) or diseases that trigger the autoimmunity, followed by the combinations of various immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.